Genelux Corporation, a late clinical-stage biopharmaceutical company, reported a net loss of $32.1 million for the year ended December 31, 2025, compared to a net loss of $29.9 million for the previous year. The company's revenue remained relatively stable at $8,000 for both years, primarily stemming from a license agreement. Operating expenses totaled $33.2 million in 2025, up from $31.7 million in 2024, with research and development expenses accounting for $19.9 million and general and administrative expenses at $13.4 million. The increase in operating expenses was mainly driven by higher clinical trial costs associated with the Phase 3 OnPrime/GOG-3076 registration trial.
The company's research and development expenses increased by $0.9 million, primarily due to an $0.8 million rise in clinical and regulatory expenses. General and administrative expenses also saw an increase of $0.7 million, mainly due to higher employee compensation costs. Other income decreased from $1.8 million in 2024 to $1.1 million in 2025, primarily due to lower bond accretion income and the absence of a gain on the extinguishment of accounts payable, which occurred in 2024. As of December 31, 2025, Genelux had cash, cash equivalents, restricted cash, and marketable securities totaling $14.6 million.
Operationally, Genelux is focused on advancing its lead product candidate, Olvi-Vec, through clinical trials. The company announced interim results from ongoing Phase 1b/2 and Phase 2 trials evaluating systemic administration of Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), respectively. These trials are designed to evaluate the efficacy and safety of Olvi-Vec in combination with chemotherapy and immune checkpoint inhibitors. The company also dosed the first patient in a Phase 2 clinical trial in the United States to evaluate Olvi-Vec in patients with recurrent NSCLC.
Genelux has been actively raising capital through public offerings. In March 2025, the company completed an underwritten offering of 3,000,000 shares of common stock, generating net proceeds of $9.6 million. In January 2026, a subsequent underwritten offering of 6,666,667 shares of common stock resulted in net proceeds of $18.5 million. The company expects its existing cash, cash equivalents, restricted cash and marketable securities, and subsequent net proceeds of $18.5 million that were received in January 2026, representing a pro forma balance of $33.1 million, to last into the first quarter of 2027. The company is also pursuing strategic collaborations, such as its license agreement with Newsoara, to support the clinical and commercial development of Olvi-Vec.
About GENELUX Corp
Genelux develops oncolytic viral immunotherapies targeting difficult-to-treat solid tumors. Its lead candidate, Olvi-Vec, is a proprietary vaccinia virus designed to selectively kill cancer cells and stimulate immune responses. The company focuses on clinical development, manufacturing, and strategic collaborations, aiming to address high unmet medical needs across multiple cancer types with off-the-shelf, personalized immunotherapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.